Motor Neurone Disease Trial, Recruiting NCT06803784 Sponsor: Neuromed IRCCS Condition: Motor Neurone Disease
Back to Motor Neurone Disease

Motor Neurone Disease Trial, Recruiting

NCT06803784
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with Parkinson's disease who show at least 2 of the 4 main symptoms (tremor, muscle stiffness, slowness of movement, or symptoms starting on one side of the body), where one of those symptoms must be tremor or slowness of movement
  • People with Parkinson's disease whose symptoms have responded to common Parkinson's medications (such as Levodopa or dopamine agonists), or who have not yet had a proper trial of these medications
  • People diagnosed with probable Alzheimer's disease (confirmed using specific brain scans or spinal fluid tests showing signs of the disease)
  • People diagnosed with ALS (motor neurone disease), confirmed as "definite" or "probable" through specific established medical guidelines and laboratory tests
  • People diagnosed with a type of dementia called Frontotemporal Dementia (FTD), confirmed using brain scans or spinal fluid tests
  • People who have both ALS and FTD, diagnosed using recognised medical guidelines

Who may not be able to join:

  • People with Parkinson's disease who have a pre-existing psychiatric condition (such as a mental health disorder diagnosed before this study)
  • People with Parkinson's disease who also have another brain or nerve condition such as multiple sclerosis, ALS, Alzheimer's, neuromuscular diseases, or epilepsy
  • People with Parkinson's disease who have also been diagnosed with dementia
  • People with Alzheimer's, FTD, or ALS who have a pre-existing psychiatric condition
  • People with Alzheimer's, FTD, or ALS who have previously been diagnosed with another neurodegenerative brain disease
  • People with Alzheimer's, FTD, or ALS who are unable to sign a consent form agreeing to take part
  • Healthy volunteers (controls) who have any pre-existing psychiatric condition
  • Healthy volunteers who have any neurodegenerative condition such as Parkinson's, multiple sclerosis, ALS, Alzheimer's, neuromuscular diseases, or epilepsy
  • Healthy volunteers who have been diagnosed with dementia or depression
  • Healthy volunteers who regularly take certain medications including anti-anxiety drugs, antidepressants, antipsychotics, sleeping tablets, or cognitive (memory/thinking) stimulant drugs

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: TERESA ESPOSITO, PhD, IRCCS INM Neuromed

Phone: +39 0865915249

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Neuromed IRCCS
Registry
ClinicalTrials.gov
Start date
4 February 2025
Est. completion
31 August 2026

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

motor symptoms of PD patients will be evaluated with Hoehn and Yahr (HY) score; motor and non motor symptoms of PD patients will be evaluated with MDS-UPDRS; clinical evaluation of cognitive impairment of PD, AD, ALS/FTD patients; clinical evaluation of ALS/FTD patients; identification of variants/mutations; Identification of protein complexes in CSF; Bioinformatic analysis for the identification of proteins and molecular pathways involved; Validation of protein complexes in plasma; Association analysis with endophenotypes; Analysis of the biological impact of protein complexes identified in C...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov